Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins.

Journal of cardiovascular pharmacology and therapeutics - 1 Jan 2001

Drmanac S, Heilbron D C, Pullinger C R, Jafari M, Gietzen D, Ukrainczyk T, Cho M H, Frost P H, Siradze K, Drmanac R T, Kane J P, Malloy M J

Abstract excerpt

BACKGROUND: The response in levels of very-low-density (VLDL) and low-density (LDL) lipoproteins varies substantially among hyperlipidemic patients during treatment with HMGCoA reductase inhibitors. Apolipoprotein E genotype and gender are known to contribute to the regulation of steady state levels of plasma lipoproteins. This study explores the effect of these and other potential determinants of the response of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoproteins E
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, VLDL

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipidemias

Share to Sex Factors

Share to Treatment Outcome

Share to Triglycerides

Source

Identifiers

PMID: 11452336
DOI: 10.1177/107424840100600106

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins.PMID 11452336Read ↗

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Semantic proximity Read ↗

Phenotypes, genotypes and response to statin therapy.Semantic proximity Read ↗

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.Semantic proximity Read ↗

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.Semantic proximity Read ↗

Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.Semantic proximity Read ↗

The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.Semantic proximity Read ↗

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.Semantic proximity Read ↗

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.Semantic proximity Read ↗

Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol.Semantic proximity Read ↗

Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women.Semantic proximity Read ↗

Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.Semantic proximity Read ↗

Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.